A preliminary study investigating effects of oral monensin sodium in an enteric Mycobacterium avium ssp. paratuberculosis infection model of calves

J Dairy Sci. 2019 Oct;102(10):9097-9106. doi: 10.3168/jds.2018-15980. Epub 2019 Aug 7.

Abstract

Mycobacterium avium ssp. paratuberculosis (MAP) is the causative agent of Johne's disease, an enteric infection of ruminants that causes significant economic burden for dairy and beef producers. Efforts to control MAP in endemic herds typically focus on herd management practices such as limiting exposure or early culling of infected animals and, occasionally, vaccination. The ionophore monensin sodium may have protective effects against MAP both in vivo and in vitro; however, this has not been thoroughly evaluated experimentally. Using a direct intestinal MAP challenge model, we have observed similarities regarding persistence of MAP in tissues and apparent resilience to infection compared with experimental oral infection or natural disease. Here we sought to investigate the effects of oral monensin supplementation in experimentally MAP-infected calves. We examined the persistence of MAP in the intestinal tissues, MAP-induced intestinal inflammation, fecal MAP shedding, and seroconversion using a commercial serologic assay. Monensin-supplemented MAP-infected calves demonstrated evidence for resilience to MAP infection earlier in this study compared with monensin-free MAP-infected calves. However, statistical modeling did not identify a significant effect of monensin on outcomes of infection, and more work is required to understand how monensin affects early tissue colonization of MAP in calves.

Keywords: Johne's disease; cattle; monensin; paratuberculosis.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Cattle
  • Cattle Diseases / drug therapy*
  • Disease Models, Animal
  • Feces / microbiology
  • Male
  • Monensin / administration & dosage
  • Monensin / therapeutic use*
  • Mycobacterium avium subsp. paratuberculosis / immunology
  • Paratuberculosis / drug therapy*
  • Paratuberculosis / microbiology

Substances

  • Anti-Bacterial Agents
  • Monensin